Canadian organization data files patent software for prebiotic dietary supplement designed from hashish waste

Tetra Bio-Pharma reports exploration the enterprise has conducted on hashish plant residue has demonstrated that what was earlier regarded “waste material” can increase the expansion of useful gut microbes.

Report information

If granted, the patent application would secure the use of hashish plant residue product that contains cannabinoids inside a specified profile selection as an “oral prebiotic element on your own or in mix with other pro, post, para or prebiotics as a nutritional dietary supplement for gastrointestinal health.”

Tetra stories that research the organization has carried out on cannabis plant residue has demonstrated that what was formerly regarded as “waste material” can improve the expansion of effective intestine microbes, together with both Lactobacillus rhamnosus and Bifidobacterium longum.

Article information

The Ottawa-primarily based business is functioning with South Carolina-primarily based Thorne HealthTech to achieve Generally Identified as Safe (GRAS) standing from the U.S. Food items and Drug Administration, most likely making it possible for the novel component to be integrated in food items and dietary health supplements.

Hashish has prolonged been linked to intestine overall health and revealed to be useful for individuals with inflammatory bowel ailment (IBD), these types of as Crohn’s and ulcerative colitis, and other gastrointestinal disorders.

“Cannabis use is frequent among individuals with IBD for symptom aid, notably amongst individuals with a history of stomach surgical treatment, chronic belly pain and/or a small quality of life index,” scientists concluded in a 2011 review revealed in European Journal of Gastroenterology & Hepatology.

A investigation assessment released in The Journal of Endocrinological Investigation located that cannabis “exerts biological features on the gastrointestinal tract by activating two varieties of cannabinoid receptors, cannabinoid variety 1 receptor (CB1 receptor) and cannabinoid form 2 receptor (CB2 receptor).”

“The endocannabinoid system could symbolize a new promising therapeutic focus on versus distinctive GI (gastrointestinal) problems, like inflammatory bowel disorders, purposeful bowel disorders and secretion- and motility-associated disorders,” researchers concluded.

Short article written content

We apologize, but this online video has failed to load. out?v=5kNQ3m3J7Xc

Subscribe to Weekend Dispensary, a new weekly e-newsletter from The GrowthOp.